|
![]() |
|
|
Fenofibrate
drug data and news
Fenofibrate drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Fenofibrate | ||
| Brand Names/Synonyms | Ankebin; Antara; CCRIS 7282; CHEMBANK1172; Elasterate; Elasterin; F6020; FNF; Fenobrate; Fenofibrate; Fenofibrate [Ban:Inn]; Fenofibrato [Inn-Spanish]; Fenofibratum [Inn-Latin]; Fenogal; Fenotard; Finofibrate; LF-178; Lipanthyl; Lipantil; Lipidex; Lipidil; Lipidil Micro; Lipidil Supra; Lipifen; Lipirex; Lipoclar; Lipofene; Liposit; Lipsin; Lofibra; Luxacor; Nolipax; Procetofen; Proctofene; Protolipan; Secalip; Sedufen; Tricor; Triglide | ||
| Indication | For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII. | ||
| Mechanism Of Action | Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. | ||
| Fenofibrate News (When available) |
Pseudoephedrine Prescriptions 07 Mar 2006 Patriot Act takes aim at meth production 07 Mar 2006 Anti-meth measure gets OK'd 07 Mar 2006 Meth battle puts ill in line 07 Mar 2006 Deputy Drug Czar: Growing Amount of Meth Coming from Mexico 07 Mar 2006 Ohio bill allows stores to make call on storage of pseudophedrine 07 Mar 2006 News Roundup 07 Mar 2006 Police, fire and courts 07 Mar 2006 Meth threatens young people at alarming rate, officials warn 07 Mar 2006 Dynavax Presents Positive TOLAMBA Phase 2/3 Results at AAAAI ... 07 Mar 2006 QUICK STUDY : A weekly digest of new research on major health ... 07 Mar 2006 DEA nets meth 'superlab' 07 Mar 2006 Fewer meth labs uncovered in 2005 07 Mar 2006 Meth law reducing number of meth labs in our state 07 Mar 2006 Auxiliary deputy spots “pill buying� at local store 07 Mar 2006 Pseudoephedrine tablets to make P worth $300,000 found at house in ... Feb 27, 2006 Significant pseudoephedrine seizure Feb 27, 2006 Governor signs pseudoephedrine restrictions into law Mar 1, 2006 Avondale restricts sale of pseudoephedrine products Feb 24, 2006 SD Law Enforcement Supports Pseudoephedrine Bill Feb 16, 2006 Keeping Pseudoephedrine Behind Pharmacy Counters Feb 17, 2006 Perrigo's pseudoephedrine woes offset by other results Feb 3, 2006 Too early to judge impact of new pseudoephedrine law Feb 4, 2006 Meth law attack problem here and abroad Mar 3, 2006 FDA Approves Clarinex-D 12 Hour (Desloratadine/Pseudoephedrine) ... Feb 2, 2006 Meth Suits Target Cold Medicine Makers, Sellers Mar 2, 2006 Over-the-counter drug works well for allergies Mar 1, 2006 State program teaches retailers about meth Mar 3, 2006 Bill regulates cold medicine used in meth Mar 3, 2006 Loopholes seen in Missouri meth law Feb 19, 2006 Talent says cold medicine law will hurt homegrown meth labs Mar 3, 2006 Global board sounds alarm over meth Mar 1, 2006 No Difference Between Over-the-Counter Decongestant and ... Mar 2, 2006 FDA Approves CLARINEX-D 12 HOUR (desloratadine 2.5mg ... Feb 2, 2006 Testing: Generic Versus Prescription Ends in a Tie Feb 27, 2006 OTC allergy drug keeps pace with Singulair Feb 20, 2006 Congress OKs landmark restrictions to fight meth Mar 3, 2006 Bureau of Narcotic Enforcement's Merchant Program Launched in ... Mar 1, 2006 Eye on KELOLAND Eye on KELOLAND Feb 22, 2006 Ex-LB officer charged in robberies Mar 3, 2006 Iowa meth bill part of federal legislation Mar 3, 2006 Meth bill to help valley? Mar 3, 2006 The meth breakthrough Mar 4, 2006 Meth education launched Mar 3, 2006 | ||
| Dosage Forms | CAPSULE; TABLET | ||
| Drug_Category | Antilipemic Agents; Fribic Acid Derivatives; ATC:C10AB05 | ||
| Absorption | Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide | ||
| Interactions |
-->Interactions for Fenofibrate: Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination. Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration. The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.
Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations. Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR. Bile acid sequestrants have been shown to bind other drugs given concurrently. Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption . Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3α-hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults. A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid. Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males. The atorvastatin Cmax values were not significantly affected by fenofibrate. The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin.
| ||
| Toxicity | Oral LD50 (mouse):1600 mg/kg. Investigated as a teratogen and reproductive hazard. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-methylethyl2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate | ||
| Chemical Formula | C20H21ClO4 | ||
| Molecular Weight | 360.831 g/mol | ||
| Smiles String | CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl | ||
| Melting Point | 80.5 °C | ||
| Water Solubility | 0.25mg/ml at 25 °C | ||
| State | Solid | ||
| LogP/Hphobicity | 5.575 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 20 hours | ||
| Protein Binding [%] | ~99% (Serum protein binding) | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cx1550.shtml http://www.drugs.com/cons/Fenofibrate.html http://www.rxlist.com/cgi/generic3/fenofibrate.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00405 | ||
| CAS Registry Number | 49562-28-9 | ||
| KEGG Compound ID | C07586 | ||
| PubChem ID | SID:180502 | ||
| PharmGKB ID | PA449594 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2250039 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |